Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Scientific Reports
|
April 6, 2023
Prospective study of weight loss and all-cause-, cardiovascular-, and cancer mortality
Liisa Tolvanen, Francesca Ghilotti, Hans-Olov Adami, et al.
Plos One
|
January 5, 2018
Physical activity, sleep and risk of respiratory infections: A Swedish cohort study
Francesca Ghilotti, Ann-Sofie Pesonen, Sara E Raposo, et al.
International Journal of Epidemiology
|
September 22, 2016
Cohort Profile: The Swedish National March Cohort
Ylva Trolle Lagerros, Essi Hantikainen, Daniela Mariosa, et al.
Journal of Comparative Effectiveness Research
|
August 20, 2024
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting
Winfried Alsdorf, Joris Diels, Francesca Ghilotti, et al.
Advances in Therapy
|
July 4, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
Rafael Fonseca, Joris Diels, Francesca Ghilotti, et al.
Hemasphere
|
December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Cancer Treatment and Research Communications
|
July 21, 2024
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study
Nicolas Girard, Keunchil Park, Se-Hoon Lee, et al.
Cancers
|
December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
Maximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Advances in Therapy
|
March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica
|
December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Scientific Reports
|
April 6, 2023
Prospective study of weight loss and all-cause-, cardiovascular-, and cancer mortality
Liisa Tolvanen, Francesca Ghilotti, Hans-Olov Adami, et al.
Plos One
|
January 5, 2018
Physical activity, sleep and risk of respiratory infections: A Swedish cohort study
Francesca Ghilotti, Ann-Sofie Pesonen, Sara E Raposo, et al.
International Journal of Epidemiology
|
September 22, 2016
Cohort Profile: The Swedish National March Cohort
Ylva Trolle Lagerros, Essi Hantikainen, Daniela Mariosa, et al.
Journal of Comparative Effectiveness Research
|
August 20, 2024
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting
Winfried Alsdorf, Joris Diels, Francesca Ghilotti, et al.
Advances in Therapy
|
July 4, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
Rafael Fonseca, Joris Diels, Francesca Ghilotti, et al.
Hemasphere
|
December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Cancer Treatment and Research Communications
|
July 21, 2024
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study
Nicolas Girard, Keunchil Park, Se-Hoon Lee, et al.
Cancers
|
December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
Maximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Advances in Therapy
|
March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica
|
December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Page
of 3